Research & Literature

Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism.

Scholl UI, Stölting G, Nelson-Williams C, et al.

eLife 2015; (4()):e06315 doi:10.7554/eLife.06315.

Outcomes of drug-based and surgical treatments for primary aldosteronism.

Steichen O, Lorthioir A, Zinzindohoue F, et al.

Advances in chronic kidney disease 2015; (22(3)):196-203.

[Hypertensive emergencies and urgencies].

Phan DG, Dreyfuss-Tubiana C, Blacher J

Presse medicale (Paris, France : 1983) 2015; (44(7-8)):737-44.

Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.

Karashima S, Yoneda T, Kometani M, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2016; (39(3)):133-7 doi:10.1038/hr.2015.129.

SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.

Douillard C, Houillier P, Nussberger J, Girerd X

Annales d'endocrinologie 2016; (77(3)):192-201.

CACNA1H(M1549V) Mutant Calcium Channel Causes Autonomous Aldosterone Production in HAC15 Cells and Is Inhibited by Mibefradil.

Reimer EN, Walenda G, Seidel E, Scholl UI

Endocrinology 2016; (157(8)):3016-22 doi:10.1210/en.2016-1170.

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

Zennaro MC, Jeunemaitre X

Annales d'endocrinologie 2016; (77(3)):214-9.

PREVELENCE OF PRIMARY ALDOSTERONISM IN AN URBAN HYPERTENSIVE POPULATION.

Galati SJ, Cheesman KC, Springer-Miller R, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2016; (22(11)):1296-1302 doi:10.4158/E161332.OR.

Familial hyperaldosteronism type III.

Monticone S, Tetti M, Burrello J, et al.

Journal of human hypertension 2017; (31(12)):776-781 doi:10.1038/jhh.2017.34.

Hypertensive crisis in children and adolescents.

Seeman T, Hamdani G, Mitsnefes M

Pediatric nephrology (Berlin, Germany) 2019; (34(12)):2523-2537 doi:10.1007/s00467-018-4092-2.

10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy.

Rossi GP, Mulatero P, Satoh F

Journal of hypertension 2019; (37(3)):603-611 doi:10.1097/HJH.0000000000001939.

Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report.

Shao D, Wang S, Zhou S, et al.

Medicine 2018; (97(50)):e13608 doi:10.1097/MD.0000000000013608.

Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

Stowasser M, Wolley M, Wu A, et al.

Current hypertension reports 2019; (21(4)):31 doi:10.1007/s11906-019-0934-y.

Primary aldosteronism associated with a germline variant in CACNA1H.

Wulczyn K, Perez-Reyes E, Nussbaum RL, Park M

BMJ case reports 2019; (12(5)) doi:10.1136/bcr-2018-229031.

Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.

Kobayashi H, Abe M, Nakamura Y, et al.

Hypertension (Dallas, Tex. : 1979) 2019; (74(3)):630-638 doi:10.1161/HYPERTENSIONAHA.119.13131.

Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism.

Adolf C, Schneider H, Heinrich DA, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020; (52(6)):386-393 doi:10.1055/a-1116-2407.

Cellular Pathophysiology of Mutant Voltage-Dependent Ca2+ Channel CACNA1H in Primary Aldosteronism.

Gürtler F, Jordan K, Tegtmeier I, et al.

Endocrinology 2020; (161(10)) doi:10.1210/endocr/bqaa135.

Taiwan mini-frontier of primary aldosteronism: Updating detection and diagnosis.

Chang CC, Chen YY, Lai TS, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(1 Pt 1)):121-129 doi:10.1016/j.jfma.2020.08.001.

11C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature.

Chen Cardenas SM, Santhanam P

Endocrine 2020; (70(3)):479-487 doi:10.1007/s12020-020-02474-3.

Enhanced Ca2+ signaling, mild primary aldosteronism, and hypertension in a familial hyperaldosteronism mouse model (Cacna1h ).

Seidel E, Schewe J, Zhang J, et al.

Proceedings of the National Academy of Sciences of the United States of America 2021; (118(17)) doi:10.1073/pnas.2014876118.

The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.

Jędrusik P, Symonides B, Lewandowski J, Gaciong Z

Frontiers in pharmacology 2021; (12()):684111 doi:10.3389/fphar.2021.684111.

A Chinese pedigree with glucocorticoid remediable aldosteronism.

Liu X, Jin L, Zhang H, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(11)):1428-1433 doi:10.1038/s41440-021-00685-3.

Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism.

Tang F, Loh LM, Foo RS, et al.

Journal of the Endocrine Society 2021; (5(11)):bvab144 doi:10.1210/jendso/bvab144.

Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.

Saiki A, Otsuki M, Tamada D, et al.

Journal of the Endocrine Society 2022; (6(1)):bvab174 doi:10.1210/jendso/bvab174.

Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review.

Han R, Jiang X

Annals of palliative medicine 2022; (11(8)):2778-2784 doi:10.21037/apm-21-3010.

Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.

Leung AA, Symonds CJ, Hundemer GL, et al.

Hypertension (Dallas, Tex. : 1979) 2022; (79(8)):1835-1844 doi:10.1161/HYPERTENSIONAHA.122.19377.

Update on the Genetics of Primary Aldosteronism and Aldosterone-Producing Adenomas.

Pitsava G, Faucz FR, Stratakis CA, Hannah-Shmouni F

Current cardiology reports 2022; (24(9)):1189-1195 doi:10.1007/s11886-022-01735-z.

Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial.

Zhou L, Jiang Y, Zhang C, et al.

Frontiers in endocrinology 2023; (14()):1124479 doi:10.3389/fendo.2023.1124479.

Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

Hundemer GL, Leung AA, Kline GA, et al.

Endocrine reviews 2024; (45(1)):69-94 doi:10.1210/endrev/bnad024.

Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.

Katsuragawa S, Goto A, Shinoda S, et al.

Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.

Should we suspect primary aldosteronism in patients with hypokalaemic rhabdomyolysis? A systematic review.

Díaz-López EJ, Villar-Taibo R, Rodriguez-Carnero G, et al.

Frontiers in endocrinology 2023; (14()):1257078 doi:10.3389/fendo.2023.1257078.

Lethal Arrhythmia Induced by Severe Hypokalemia with Primary Aldosteronism: A Case Report and Literature Review.

Hirose R, Tsurutani Y, Nakatsue T, et al.

Internal medicine (Tokyo, Japan) 2024; (63(10)):1405-1413 doi:10.2169/internalmedicine.1931-23.

Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism.

Jahan S, Yang J, Hu J, et al.

Endocrine connections 2024; (13(3)).

Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism.

Araujo-Castro M, Parra P, Martín Rojas-Marcos P, et al.

Frontiers in endocrinology 2024; (15()):1336306 doi:10.3389/fendo.2024.1336306.

Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis.

Ho WY, Hsiao CC, Wu PH, et al.

Therapeutic advances in chronic disease 2024; (15()):20406223241239775 doi:10.1177/20406223241239775.

Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

Mulatero P, Scholl UI, Fardella CE, et al.

European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.

Genetic Testing for Primary Aldosteronism in SPAIN: Results From the SPAIN-ALDO Registry and Review of the Literature.

Araujo-Castro M, Ruiz-Sánchez JG, Gonzalvo C, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(5)):e1573-e1579 doi:10.1210/clinem/dgae523.

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.

Adler GK, Stowasser M, Correa RR, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.

Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain.

Goi J, Paja Fano M, Rizo Gellida A, et al.

European journal of endocrinology 2025; (193(2)):297-309 doi:10.1093/ejendo/lvaf158.

Primary aldosteronism and long-term outcomes using PAMO definition.

Chu WK, Lai CF, Chiang S, et al.

Hypertension research : official journal of the Japanese Society of Hypertension 2026; (49(2)):457-468 doi:10.1038/s41440-025-02324-7.

[Analysis of a family with familial hyperaldosteronism type Ⅳ due to a mutation in the CACNA1H gene].

Zhu ZF, Li AZ, Yan ZL, et al.

Zhonghua yi xue za zhi 2025; (105(35)):3090-3094 doi:10.3760/cma.j.cn112137-20250409-00883.

Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis.

Katsuragawa S, Le MV, Fuller PJ, Yang J

The lancet. Diabetes & endocrinology 2025; (13(12)):1041-1053 doi:10.1016/S2213-8587(25)00263-3.

Recurrent CACNA1HE282K is a gain-of-function mutation associated with primary hyperaldosteronism.

Li R, Jiang Y, Chen Q, et al.

European journal of endocrinology 2026; (194(1)):22-34 doi:10.1093/ejendo/lvaf253.

Treatment of Primary Aldosteronism.

Parisien-La Salle S, Hundemer GL, Nehs MA, et al.

Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.

Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management of CACNA1H-Related Primary Aldosteronism: A Systematic Review.

Michalski W, Jaszczyszyn I, Bielska W, Stolarczyk A

Journal of clinical medicine 2026; (15(10)) doi:10.3390/jcm15103693.

Primary aldosteronism.

Vaidya A, Kline GA, Mulatero P, et al.

Nature reviews. Disease primers 2026; (12(1)).

Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

Sawyer NK, Glendenning P, Schlaich MP, et al.

Pathology 2026; (58(5)):501-506 doi:10.1016/j.pathol.2026.04.003.

Decision Tree Prediction of Saline Infusion Test Outcomes in Suspected Primary Aldosteronism: A Multicenter CDM Study.

Kim KJ, Choi J, Baek N, et al.

The Journal of clinical endocrinology and metabolism 2026; doi:10.1210/clinem/dgag325.

Primary aldosteronism with intellectual disability associated with CACNA1H and PPP2R5D mutations: a case report with review of literature.

Zhang W, Zhang Y, Wang Y, et al.

Endocrine journal 2026; doi:10.1507/endocrj.EJ26-0175.

Evaluation of Current Screening Thresholds for the Detection of Primary Aldosteronism.

Voorhies KR, Bi C, Adeyemo MA, et al.

Hypertension (Dallas, Tex. : 1979) 2026; (83(11)):e27634 doi:10.1161/HYPERTENSIONAHA.126.27634.